Education
About Us
Working with TipRanks
Follow Us
Entero Therapeutics (ENTO)
NASDAQ:ENTO
ENTO Stock Chart & Stats
$2.32
-$0.06(-8.82%)
At close: 4:00 PM EST
$2.32
-$0.06(-8.82%)
Day’s Range― - ―
52-Week Range$0.97 - $5.84
Previous Close$0.65
Volume60.40K
Average Volume (3M)123.51K
Market Cap
$9.38M
Enterprise ValueN/A
Total Cash (Recent Filing)$2.52M
Total Debt (Recent Filing)$835.61K
Price to Earnings (P/E)―
Beta0.63
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.65
Shares Outstanding3,361,903
10 Day Avg. Volume103,985
30 Day Avg. Volume123,511
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.56
Revenue Forecast (FY)N/A
Entero Therapeutics News
ENTO FAQ
What was Entero Therapeutics’s price range in the past 12 months?
Entero Therapeutics lowest stock price was $0.97 and its highest was $5.84 in the past 12 months.
What is Entero Therapeutics’s market cap?
Entero Therapeutics’s market cap is $9.38M.
When is Entero Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Entero Therapeutics’s earnings last quarter?
Currently, no data Available
Is Entero Therapeutics overvalued?
According to Wall Street analysts Entero Therapeutics’s price is currently Overvalued.
Does Entero Therapeutics pay dividends?
Entero Therapeutics does not currently pay dividends.
What is Entero Therapeutics’s EPS estimate?
Entero Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entero Therapeutics have?
Entero Therapeutics has 3,361,903 shares outstanding.
What happened to Entero Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Entero Therapeutics?
Currently, no hedge funds are holding shares in ENTO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Entero Therapeutics
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Technical Analysis
Alaunos Therapeutics
―
PharmaCyte Biotech
―
Ensysce Biosciences
―
SciSparc Ltd.
―
Polyrizon Ltd.
―
Ownership Overview
0.51% Insiders
0.52% Mutual Funds
0.35% Other Institutional Investors
98.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---